Fill in the form below and our experts will get back to you within 1 business day.
CD Biosynsis engineers microbial cell factories for next-generation biodegradable polymers. From PHA and PLA to specialty bioplastics, we deliver production strains optimized for performance, cost, and sustainability metrics.
Serving the Biopolymer & Sustainable Materials Ecosystem
Material Science Institutes
Polymer chemistry research centers
Packaging Manufacturers
Bio-based packaging innovators
Chemical Corporations
Renewable chemical producers
Sustainable Brands
Eco-conscious product companies
End-to-end infrastructure for biopolymer development and commercialization
Engineered biosynthesis for PHA, PLA, PBS, and specialty polyesters
Molecular weight, crystallinity, and mechanical property tuning
From shake flask to industrial bioreactor production
GPC, DSC, TGA, and mechanical property testing
The biopolymer industry faces critical sustainability and economic challenges. Our synthetic biology platform addresses these through precision-engineered production systems.
Over 90% of plastics originate from petroleum, creating carbon emissions and environmental pollution. Engineered microbes produce identical or superior materials from renewable feedstocks like corn starch and sugarcane.
First-generation bioplastics face cost barriers versus petroleum-based plastics. Our metabolic engineering and fermentation optimization reduce production costs to achieve competitive pricing.
Meeting diverse application requirements for tensile strength, flexibility, and thermal resistance. We engineer polymer characteristics through pathway modification and strain optimization.
Platform Approach
40% faster development
We engineer microbial production platforms for biodegradable polymers and bio-based materials. From pathway construction to pilot-scale validation, our team delivers production-ready strains with optimized polymer characteristics.
Engineering Pseudomonas, Cupriavidus, and E. coli for polyhydroxyalkanoate production. Tailored monomer composition (C4-C14) achieves specific thermal and mechanical properties.
Constructing heterologous lactide production pathways in industrial yeast. Optimizing polymer tacticity for enhanced thermal stability and mechanical performance.
Designing microbial pathways for adipic acid, succinic acid, and 1,4-butanediol. Enabling 100% bio-derived conventional plastics.
Engineering controlled polymer degradation pathways. Creating materials that maintain performance during use but degrade on-demand at end-of-life.
Scale-up from shake flask to pilot bioreactor. Optimizing media composition, feeding strategies, and downstream processing.
Comprehensive analytical packages for polymer validation. GPC, HPLC, LC-MS, DSC, TGA, and mechanical testing.
Why the materials industry is transitioning to biologically-produced polymers
| Parameter | Chemical Inputs | Synthetic Biology |
|---|---|---|
| Feedstock Origin | Petroleum-derived chemical synthesis | Renewable biomass fermentation |
| Carbon Footprint | High emissions from extraction and processing | Low carbon from biological fixation |
| End-of-Life | Persists 100-500 years in landfill | Biodegradable within 1-5 years |
| Production Energy | 200-300°C energy-intensive processes | 30-37°C ambient conditions |
| Toxicity Profile | Hazardous monomers and catalysts | Generally recognized as safe (GRAS) |
Integrated capabilities for polymer-producing strain development, process optimization, and material characterization.
CRISPR-Cas9, recombineering, and Gibson assembly for polymer pathway engineering
GPC, HPLC, LC-MS/MS for molecular characterization and pathway intermediates
Shake flask to bioreactor with DoE-based media and process optimization
DSC, TGA, tensile testing, and barrier property analysis
We function as your external strain engineering and metabolic pathway team. Whether you need a single engineered chassis or a complete pathway optimization pipeline, we deliver publication-quality data and transfer-ready strains.
Each project is assigned a dedicated PhD-level scientist as primary contact, ensuring technical continuity and rapid decision-making throughout development.
Engage us for full end-to-end development or specific phases (strain engineering only, fermentation optimization only, etc.). Scale investment according to your validation needs.
All proprietary strains and sequences remain your exclusive property. We offer clean IP transfer with no residual license claims or downstream revenue sharing requirements.
In-house regulatory affairs team experienced with ASTM D6400, FDA FCN, and REACH guidelines. We prepare submission-ready dossiers for your target markets.
Concept to pilot validation. Includes strain engineering, fermentation optimization, and greenhouse testing.
Genetic modification and characterization. Deliverables include sequence-confirmed strains and technical reports.
Process development and optimization. From lab-scale proof to pilot-scale production parameters.
Characterization, stability testing, and regulatory dossier preparation for submission.
Get answers to common questions about our biopolymer engineering solutions. our team for project-specific inquiries.
We have established platforms for PHAs (PHB, PHBV, mcl-PHA), PLA precursors, polybutylene succinate (PBS), and bio-based diacids. Custom polymer targets can be developed based on your material requirements.
Through monomer composition control, we achieve target molecular weights (10-1000 kDa), crystallinity levels (20-70%), and mechanical properties (tensile strength 10-100 MPa, elongation 5-500%).
Standard chassis engineering takes 8-12 weeks to sequence-confirmed strain. Pathway optimization requires 4-6 months. De novo pathway construction extends to 6-10 months including proof-of-concept validation.
We offer consultation on cell disruption, polymer extraction, and purification protocols. DSP technology transfer to contract manufacturers can be facilitated for commercial production.
Regulatory classification depends on your final product and modification approach. We can engineer strains using methods that may qualify for streamlined review (e.g., self-cloning, site-directed mutagenesis). Our regulatory team provides guidance on ASTM D6400 / EN 13432 (Compostability Standards), FDA Food Contact Notifications (FCN), and REACH compliance. We support degradation rate documentation for marine and soil environments. during the project design phase to ensure your strain aligns with your intended regulatory pathway.
Get a customized quote for your Biopolymer project. Our experts will respond within 24 hours.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.